Lymphoblastic lymphoma (LBL) is caused by multifactorial genetics changes that interrupt the normal progression of lymphoid tissues. Given our extensive background in developing therapies for LBL, Protheragen is uniquely able to offer customized strategies and complete assistance to help you advance from research in LBL therapy to its commercialization.
Lymphoblastic lymphoma (LBL) is marked as an aggressive subtype of non-Hodgkin lymphoma (NHL) which stems from the malignant proliferation of immature T or B cell precursors. LBL consists of nearly 2% of NHL in adults and 30-40% in children. It is characterized by a bimodal distribution of age, with young adults as well as older adults showing increased incidence.
| Subtypes | Prevalence | Malignant Proliferating Cells | Mutant Genes | |
|---|---|---|---|---|
| T-LBL | ~85-90% of LBL cases | Immature T-cell precursors |
|
|
| B-LBL | ~10-15% of LBL cases | Immature B-cell precursors |
|
|
The pathogenesis of lymphoblastic lymphoma (LBL) involves genetic mutations that disrupt the normal development of lymphocytes, resulting in uncontrolled proliferation of immature T or B cell precursors. The mutated genes involved in the two subtypes of LBL are shown in the table above, and both exhibit metabolic reprogramming, cytokine-dependent survival, and immune escape mechanisms. The tumor microenvironment further promotes tumor progression through stromal interactions and immunosuppressive signals.
Fig.1 Pathogenesis of two disease subtypes, T-LBL and B-LBL. (Temple, William C., et al., 2023)
| Therapy | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Anti-CD19 CAR-T | Direct cytotoxicity against CD19+ B-cells. | CD19 | NCT06709469 | Approved |
| Inotuzumab Ozogamicin | Delivers calicheamicin (DNA-damaging agent) to CD22+ cells. | CD22 | NCT06427330 | Approved |
| Rituximab+mVPDL | Induces antibody-dependent cellular cytotoxicity (ADCC) and DNA damage. | CD20/DNA | NCT01429610 | Phase II |
| JCAR015 | Enhanced T-cell activation/persistence. | CD19 | NCT02973191 | Phase II |
| Ixazomib | Blocks NF-κB signaling and induces apoptosis in malignant lymphocytes. | Proteasome β5 subunit | NCT03888534 | Phase I |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
At Protheragen, we specialize in providing comprehensive research and development solutions for lymphoblastic lymphoma (LBL). Our expertise spans diagnostic development, targeted therapeutic development, precision disease modeling, and rigorous preclinical evaluation. We support the advancement of novel therapeutics including CAR-T cells, antibody-drug conjugates (ADCs), and small molecule inhibitors with biologically relevant LBL-specific models.
Protheragen takes great pride in providing integrated preclinical services for lymphoblastic lymphoma (LBL). These services cover all aspects of drug research including pharmacodynamics (PD), pharmacokinetics (PK), and safety. We observe the highest quality and ethics in the execution of all our research services to make certain the outcome is dependable. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)